Abstract
All New Zealand residents are covered by a national public health system, and approximately 80 % of all health expenditure is publically financed. A well-regulated system of privately owned pharmacies supplies outpatient pharmaceuticals, while inpatient pharmaceuticals are provided in secondary care facilities. New Zealand does not use pharmaceutical price controls, leaving prices to be determined by negotiation. However, the public health system has a very effective monopsony purchaser, the Pharmaceutical Management Agency of New Zealand (PHARMAC). PHARMAC negotiates the prices of inpatient, outpatient and cancer pharmaceuticals, vaccines and medical devices, and manages a capped national budget for outpatient and cancer pharmaceuticals. PHARMAC also sets (separate) national positive formularies of publically funded outpatient and inpatient pharmaceuticals, and administers access schemes for pharmaceuticals that are not on these formularies. PHARMAC uses a variety of mechanisms to obtain favourable prices, including competitive tendering, sole supply contracts, reference pricing, bundling deals, risk sharing agreements and promoting use of generics. Health technology assessment is used extensively in decision making and price negotiations. As a result, New Zealanders have universal and nationally consistent pharmaceutical coverage, with lower patient pharmaceutical co-payments than many comparable countries.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aaltonen K, Ragupathy R, Tordoff J, Reith D, Norris P (2010) The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand. Value Health 13(1):148–156
Babar Z-U-D, Francis S (2014) Identifying priority medicines policy issues for New Zealand. BMJ Open 4(5):e004415
Babar Z-U-D, Vitry A (2014) Differences in Australian and New Zealand medicines funding policies. Australian Prescriber 2014, Online First 8th July. http://www.australianprescriber.com/online-first/54/differences-in-australian-and-new-zealand-medicines-funding-policies
Begg E, Sidwell A, Gardiner S, Nicholls G, Scott R (2003) The sorry saga of statins in New Zealand—pharmacopolitics versus patient care. N Z Med J 116(1170):U360
Best Practice Advocacy Centre New Zealand (2013) Upfront: unapproved medicines and unapproved uses of medicines: keeping prescribers and patients safe. Best Pract J 51
Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme (BODE) (2011) Costing of pharmaceuticals in New Zealand for health economic studies: backgrounder and protocol for costing. Public Health Monograph Series, No. 20, Technical report no. 6. ISSN: 1178–7139. Department of Public Health, University of Otago, Wellington
Business and Economic Research Limited (BERL) (2005) Independent review of the Castalia report on New Zealand pharmaceutical policies. http://www.pharmac.govt.nz/2006/05/04/040506b.pdf. 2014
Castalia Strategic Advisors (2005) New Zealand pharmaceutical policies: time to take a fresh look. http://www.castalia-advisors.com/files/14634.pdf. 2014
Central Region’s Technology Advisory Services Pharmacy Today (2014) New service model for community pharmacy. http://webcache.googleusercontent.com/search?q=cache:tAHjiOt2P7sJ:www.pharmacytoday.co.nz/media/349234/pharmacy_services_agreement_q_a.doc+&cd=1&hl=en&ct=clnk&gl=n. 2014
Cumming J, Mays N, Daubé J (2010) Analysis: how New Zealand has contained expenditure on drugs. BMJ 340:c2441
Derek R, King R, Kanavos P (2002) Encouraging the use of generic medicines: implications for transition economies. Croat Med J 43(4):462–469
Dew K, Davis A (2014) Limits to neoliberal reforms in the health sector: the case of pharmaceutical management in New Zealand. Int J Health Serv 44(1):137–153
Easton B (2005) New Zealand’s pharmaceutical policies: a fresh look. http://www.pharmac.govt.nz/2006/05/04/040506a.pdf. 2014
Grocott R, Metcalf S, Alexander P, Werner R (2013) Assessing the value for money of pharmaceuticals in New Zealand—PHARMAC’s approach to cost-utility analysis. N Z Med J 126 (1378)
Health Funds Association of New Zealand (2013) Annual review: 2013. http://www.healthfunds.org.nz/pdf/2013-annual-review.pdf. 2014
Isaacs R, Frampton C, Kuper-Hummel M (2007) PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision. N Z Med J 120 (1259)
Kilpatrick K, Vogler S, Babar Z (2014) Proceedings of the Waikato Clinical School Biannual Research Seminar, March 2014. Analysis of prices of medicines in Europe and in New Zealand. N Z Med J 127 (1393)
Lakdawalla D, Yin W (2013) Insurers’ negotiating leverage and the external effects of Medicare part D. National Bureau of Economic Research, Boston
MacKay P (2005) Is PHARMAC’s sole-supply tendering policy harming the health of New Zealanders? N Z Med J 118(1214):U1433
Management Sciences for Health (2012) Pharmaceutical pricing policy. Management Sciences for Health, Medford
McCormack P, Quigley J, Hansen P (2009) Review of access to high cost, highly specialised medicines in New Zealand. Report to Minister of Health, Hon Tony Ryall. Wellington
Medicines Act (1981) Effect of licences. 118, vol. 1e. Wellington
Metcalf S, Rodgers A, Werner R, Schousboe C (2012) PHARMAC has no cost-effectiveness threshold. N Z Med J 125 (1350)
Morgan S, Kennedy J (2010) Prescription drug accessibility and affordability in the United States and abroad. Commonw Fund 89:1–12
Morgan S, McMahon M, Mitton C, Roughead E, Kirk R, Kanavos P, Menon D (2006) Centralized drug review processes in Australia, Canada, New Zealand and the United Kingdom. Health Aff (Millwood) 25(2):337–347
Morgan S, Hanley G, McMahon M, Barer M (2007) Influencing drug prices through formulary-based policies: lessons from New Zealand. Health Policy 3(1):121–140
MIMS New Ethicals (2014) January–June 2014 edn. UBM Medica NZ, Auckland
New service model for community pharmacy (2012). Best Prac J (45)
New Zealand District Health Boards (2007) DHB shared services: pharmacy services agreement for the provision of pharmacy services. http://www.dhbsharedservices.health.nz/site/sig/npsf/toolkit/service-agreements.aspx. 2014
Organisation for Economic Co-operation and Development (2010) Value for money in health spending: drawing all the benefits from pharmaceutical spending
Pharmaceutical Management Agency (2013) Pharmaceutical Management Agency annual report 2012/13. Wellington
Pharmaceutical Management Agency (PHARMAC) (2013) Named patient pharmaceutical assessment (exceptional circumstances) policy. http://www.pharmac.health.nz/assets/nppa-policy-2013-07.pdf
Pharmaceutical Management Agency (PHARMAC) (2014a) Named Patient Pharmaceutical Assessment (NPPA) Questions and Answers for clinicians. http://www.pharmac.health.nz/assets/nppa-clinician-info-sheet.pdf
Pharmaceutical Management Agency (PHARMAC) (2014b) PHARMAC and hospital medical devices. http://www.pharmac.health.nz/medicines/hospital-devices
Pharmaceutical Management Agency of New Zealand (PHARMAC) (2014c) http://www.pharmac.health.nz
Pharmaceutical Society of New Zealand (2014) What is pharmacy? http://www.psnz.org.nz/public/home/careers/intro.aspx
Raftery J (2008) Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust 188(1):26–28
Ragupathy Y (2013) New Zealanders’ access to licensed and subsidised medicines compared with a nationwide single payer system in each of Australia, the United Kingdom and the United States. Doctor of Philosophy, University of Otago, Dunedin
Ragupathy R, Aaltonen K, Tordoff J, Norris P, Reith D (2012a) A 3-dimensional view of access to licensed and subsidized medicines under single payer systems in the United States, United Kingdom, Australia and New Zealand. Pharmacoeconomics 30(11):1051–1065
Ragupathy R, Tordoff J, Norris P, Reith D (2012b) Key informants perceptions of how PHARMAC operates in New Zealand. Int J Technol Assess Health Care 28(4):367–373
Ragupathy R, Udin-Babar Z, Chandra H, Daiya M, Girn M, Mirza W, Yousif A (2012c) Proceedings of the Waikato Clinical School biannual research seminar, March 2012. Son of Doctor Strangelove: how we learned to stop worrying and love PHARMAC (New Zealand consumers’ perceptions of private insurance for pharmaceuticals). N Z Med J 125(1352)
The Accident Compensation Corporation (2013) ACC frequently asked questions. http://www.acc.co.nz/about-acc/media-centre/frequently-asked-questions/index.htm. Accessed June 2014
The Australia New Zealand Therapeutic Products Agency (2014) Transition to the Australia New Zealand Therapeutic Products Agency. http://www.anztpa.org/index.htm. 2014
The Commonwealth Fund (2010) International profiles of health care systems
The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) (2013) About Medsafe. http://www.medsafe.govt.nz/other/about.asp#pre. 2014
The New Zealand Ministry of Health (2010) Pharmacy licensing. http://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicines-control/pharmacy-licensing. 2014
The New Zealand Ministry of Health (2011a) Accident cover. https://www.health.govt.nz/new-zealand-health-system/publicly-funded-health-and-disability-services/accident-cover. 2014
The New Zealand Ministry of Health (2011b) Publically funded health services. https://www.health.govt.nz/new-zealand-health-system/publicly-funded-health-and-disability-services. 2014
The New Zealand Ministry of Health (2011c) Visiting a dentist. https://www.health.govt.nz/new-zealand-health-system/publicly-funded-health-and-disability-services/visiting-dentist. 2014
The New Zealand Ministry of Health (2013a) Funding. http://www.health.govt.nz/new-zealand-health-system/overview-health-system/funding. 2014
The New Zealand Ministry of Health (2013b) Vaccine purchasing. http://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/immunisation-programme-decisions/vaccine-purchasing. 2014
The New Zealand Ministry of Health (2014a) Enrolment in a primary health organisation. http://www.health.govt.nz/our-work/primary-health-care/about-primary-health-organisations/enrolment-primary-health-organisation. 2014
The New Zealand Ministry of Health (2014b) Prescription charges. http://www.health.govt.nz/your-health/conditions-and-treatments/treatments-and-surgery/medications/prescription-charges. 2014
The New Zealand Parliament (2000) New Zealand public health and disability act, Wellington
The Organisation for Economic Co-operation and Development (2013) Health at a glance 2013-OECD indicators
The Pharmaceutical Management Agency of New Zealand (PHARMAC) (2006) Operating policies and procedures of the Pharmaceutical Management Agency (“PHARMAC”). 3rd ed., Wellington
The Pharmaceutical Management Agency of New Zealand (PHARMAC) (2012a) Introduction to PHARMAC. http://www.pharmac.health.nz/assets/infosheet-01-intro-2013.pdf. 2014
The Pharmaceutical Management Agency of New Zealand (PHARMAC) (2012b) Our place in the system. http://www.pharmac.health.nz/assets/infosheet-01-intro-2013.pdf. 2014
The Pharmaceutical Management Agency of New Zealand (PHARMAC) (2013) PHARMAC’s history. http://www.pharmac.health.nz/assets/infosheet-02-history-2013.pdf. 2014
The Pharmaceutical Management Agency of New Zealand (PHARMAC) (2014a) Pharmac’s decision criteria—proposal for change. Wellington
The Pharmaceutical Management Agency of New Zealand (PHARMAC) (2014b) Purchasing medicines. http://www.pharmac.health.nz/assets/infosheet-05-purchasing-medicines-2013.pdf
The Pharmaceutical Management Agency of New Zealand (PHARMAC) (2014c) Setting and managing the combined pharmaceutical budget. http://www.pharmac.health.nz/assets/infosheet-08-community-pharm-budget-2013.pdf
The Pharmaceutical Management Agency of New Zealand (PHARMAC), Evans J (2008) Freeing up funds: fluoxetine 20 mg capsules. http://www.pharmac.govt.nz/2008/07/03/Pharmaceutical%20Funding%20presentation.pdf. 2014
Tordoff J (2007) Evaluating the impact of a national hospital pharmaceutical strategy in New Zealand. University of Otago, Dunedin
United States Department of Commerce: International Trade Administration (2004) Pharmaceutical price controls in OECD countries. Implications for U.S. consumers, pricing, research and development, and innovation. Washington
Wilson K, Bloor R, Jennings D (eds) (2014) New Zealand Pharmaceutical Schedule. Pharmaceutical Management Agency, Wellington
Wonder M, Milne R (2011) Access to new medicines in New Zealand compared to Australia. N Z Med J 124(1346)
Woodfield A (2001) Augmenting reference pricing of pharmaceuticals in New Zealand with strategic cross-product agreements. Pharmacoeconomics 19(4):365–377
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Glossary
- ACC
-
Accident Compensation Corporation
- ANZTPA
-
Australia New Zealand Therapeutic Products Agency
- DHB
-
District Health Board
- HML
-
Hospital Medicines List
- Medsafe
-
New Zealand Medicines and Medical Devices Safety Authority
- NICE
-
National Institute for Health and Care Excellence (United Kingdom)
- NPPA
-
Named Patient Pharmaceutical Assessment
- OECD
-
Organisation for Economic Co-operation and Development
- PHARMAC
-
Pharmaceutical Management Agency of New Zealand
- PHO
-
Primary Health Organisation
- PTAC
-
Pharmacology and Therapeutics Advisory Committee
- QALY
-
Quality Adjusted Life Year
- TGA
-
Therapeutic Goods Administration (Australia)
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ragupathy, R., Kilpatrick, K., Babar, ZUD. (2015). Pharmaceutical Pricing in New Zealand. In: Babar, ZUD. (eds) Pharmaceutical Prices in the 21st Century. Adis, Cham. https://doi.org/10.1007/978-3-319-12169-7_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-12169-7_11
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-12168-0
Online ISBN: 978-3-319-12169-7
eBook Packages: Business and EconomicsEconomics and Finance (R0)